Popov D.A., Plyush M.G., Ovseenko S.T., Abramyan M.V., Podshekoldina O.O., Yaroustovsky M.B.
Purpose of the study was to define prognostic ability of presepsin (sCD14-ST) as a
predictor of complications
in cardiac surgical patients during perioperative period. Methods; Patients operated for acquired heart
valvular diseases with cardiopulmonary bypass were involved in the study (n=51, age 58±11 years).
Following parameters were studied; demographic data, duration of cardiopulmonary bypass, time of aorta
clamping, severity-of-disease by APACHE II scale before surgery, on 1st, 2nd, 3rd and 6th day after surgery,
routine clinical laboratory data and sCD14-ST. Results; there were no clinical laboratory evidences of
inflammation before surgery in all patients. There was no difference between biomarkers in patients who had
normal condition during postoperative period and in patients who had complications and/or untoward
outcomes during postoperative period. Presepsin level in 6 patients (11.8%) was 543 (519-602) ng/ml,
maximal 1597 ng/ml. Infection complications accrued in 19 patients (37%). Hospital mortality was 13.7 % (7
patients), all cases of death was in group of patients with infection complications. Statistically significant
differences in the level of presepsin and severity-of-disease by APACHE II in groups of patients with
infection complications and without accrued on 1st and 2nd days of postoperative period. Optimal split point
were 702 ng/ml, 8.5 points and 3.3 ng/ml. Increased postoperative level of presepsin is associated with a risk
of infection complications and untoward outcomes. Conclusion; sCD14-ST monitoring with the use of
severity-of-disease scales and recent biomarkers allow to identify patients with high risk of infection
complications and untoward outcomes.
Key words: cardiac surgery, systemic infl ammation, biomarkers, presepsin, sCD14-ST
Dostları ilə paylaş: